

# Product datasheet

info@arigobio.com

## ARG82994 Human Tau ELISA Kit

Package: 96 wells Store at: 4°C

#### Summary

Product Description ARG82994 Human Tau ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human Tau in

cell culture supernatant, serum, plasma, cell / tissue extracts.

Tested Reactivity Hu

Tested Application ELISA

Target Name Tau

Conjugation HRP

Conjugation Note Substrate: TMB and read at 450 nm

Sensitivity 20 pg/ml

Sample Type Cell culture supernatant, serum, plasma, cell / tissue extracts

Standard Range 40.625 - 2600 pg/ml

Sample Volume  $50 \mu l$ 

Alternate Names TAU; Neurofibrillary tangle protein; Paired helical filament-tau; PPND; DDPAC; FTDP-17; MTBT2;

Microtubule-associated protein tau; PHF-tau; MSTD; PPP1R103; MTBT1; MAPTL

### **Application Instructions**

Assay Time ~ 1.5 hour

### **Properties**

Form 96 well

Storage instruction Store the kit at 2-8°C. Keep microplate wells sealed in a dry bag with desiccants. Do not expose test

reagents to heat, sun or strong light during storage and usage. Please refer to the product user manual

for detail temperatures of the components.

Note For laboratory research only, not for drug, diagnostic or other use.

#### **Bioinformation**

Gene Symbol MAPT

Gene Full Name microtubule-associated protein tau

Background This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes

complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and

progressive supranuclear palsy. [provided by RefSeq, Jul 2008]

Function Promotes microtubule assembly and stability, and might be involved in the establishment and

maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus

www.arigobio.com argo.nuts about antibodies 1/2

binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. [UniProt]

Highlight

Related products:

<u>Tau antibodies</u>; <u>Tau ELISA Kits</u>; <u>Tau Duos / Panels</u>; New ELISA data calculation tool: <u>Simplify the ELISA analysis by GainData</u>

PTM

Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5, GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in the form associated with paired helical filaments (PHF-tau)), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK1 or MARK2), causing detachment from microtubules, and their disassembly. Phosphorylation decreases with age. Phosphorylation within tau/MAP's repeat domain or in flanking regions seems to reduce tau/MAP's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis. Phosphorylation at Ser-548 by GSK3B reduces ability to bind and stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and BRSK2 in neurons affects ability to bind microtubules and plays a role in neuron polarization. Phosphorylated at Ser-554, Ser-579, Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 by SGK1 mediates microtubule depolymerization and neurite formation in hippocampal neurons. There is a reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces glycosylation by a factor of 2 and 4 respectively. Phosphorylation on Ser-721 is reduced by about 41.5% by GlcNAcylation on Ser-717. Dephosphorylated at several serine and threonine residues by the serine/threonine phosphatase PPP5C.

Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.

O-glycosylated. O-GlcNAcylation content is around 8.2%. There is reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces O-GlcNAcylation by a factor of 2 and 4 respectively. O-GlcNAcylation on Ser-717 decreases the phosphorylation on Ser-721 by about 41.5%.

Glycation of PHF-tau, but not normal brain TAU/MAPT. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.